Advertisement

Advances in Therapy

, Volume 36, Issue 12, pp 3356–3367 | Cite as

Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis

  • Jia Wei
  • Cai-shuang Pang
  • Juan Han
  • Hao YanEmail author
Original Research

Abstract

Introduction

The effect of N-acetylcysteine (NAC) treatment for patients with chronic bronchitis (CB) is controversial. To better understand the role of NAC in CB treatment, we performed a meta-analysis to provide a more accurate estimation of the importance of NAC treatment.

Methods

PubMed, Embase, and CNKI were systematically searched. The pooled relative risk (RR) and 95% confidence intervals (CI) were calculated using either fixed-effect model or random-effect model based on heterogeneity examination. Statistical analyses were performed using the STATA 12.0 and RevMan 5.2.

Results

A total of 11 publications with 775 patients who were taking NAC and 789 controls who were taking placebo were judged eligible regarding inclusion criteria. The pooled analysis demonstrated significant evidence that NAC reduced the frequency of CB exacerbations (RR = 0.81, 95% CI 0.69–0.93, P = 0.004). Patients treated with NAC had significant symptom improvement compared with controls (RR = 1.68, 95% CI 1.13–2.52, P = 0.01). NAC did not significantly increase the risk of adverse effects compared with placebo (RR 0.86, 95% CI 0.67–1.09, P = 0.22). Subgroup analysis was carried out to assess the stability of results. No publication bias was detected during analyses.

Conclusion

There is a role for NAC treatment in the management of CB by reducing symptoms and exacerbations compared with placebo, without increasing the risk of adverse effects. A regular treatment of low dosage (< 1200 mg per day) and a duration of at least 3 months seems to be effective.

Keywords

Chronic bronchitis N-Acetylcysteine Meta-analysis 

Notes

Acknowledgements

We are grateful to the authors of the primary studies included in this meta-analysis and thank Jun-fei Hu for his review and valuable feedback of the manuscript.

Funding

Sponsorship for this study and article processing charges were funded by projects in the Science and Technology Pillar Program from the Department of Science and Technology of Sichuan province (2015SZ0111). All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authors’ Contribution

Jia Wei and Hao Yan initiated and coordinated the study. Cai-shuang Pang and Juan Han were responsible for the data collection and data analysis. Studies were reviewed by Hao Yan. Jia Wei wrote the first draft of the manuscript. All the authors were involved in the interpretation of the analyses and gave input to the final manuscript.

Disclosures

Jia Wei, Cai-shuang Pang, Juan Han, and Hao Yan have nothing to disclosure.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

All data generated or analyzed during our study are included in this published article/as supplementary information files.

References

  1. 1.
    American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77–121.Google Scholar
  2. 2.
    Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):345–65.CrossRefGoogle Scholar
  3. 3.
    Stavem K, Sandvik L, Erikssen J. Can Global Initiative for Chronic Obstructive Lung Disease stage 0 provide prognostic information on long-term mortality in men? Chest. 2006;130(2):318–25.CrossRefGoogle Scholar
  4. 4.
    Xinzhi W. Chronic obstructive pulmonary disease and pulmonary heart disease (Chinese). Beijing: Beijing Press; 1999.Google Scholar
  5. 5.
    Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med. 2015;175(9):1539–49.CrossRefGoogle Scholar
  6. 6.
    Huchon GJ, Vergnenegre A, Neukirch F, Brami G, Roche N, Preux PM. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J. 2002;20(4):806–12.CrossRefGoogle Scholar
  7. 7.
    Donaldson G, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–52.CrossRefGoogle Scholar
  8. 8.
    Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16(2):253–62.CrossRefGoogle Scholar
  9. 9.
    Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM. 1995;88(1):61–8.PubMedGoogle Scholar
  10. 10.
    Medici TC, Radielovic P. Effects of drugs on mucus glycoproteins and water in bronchial secretion. J Int Med Res. 1979;7(5):434–42.CrossRefGoogle Scholar
  11. 11.
    Rahman I, Skwarska E, MacNee W. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax. 1997;52(6):565–8.CrossRefGoogle Scholar
  12. 12.
    Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187–94.CrossRefGoogle Scholar
  13. 13.
    Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS). Eur Respir J. 1995;8(8):1398-420.CrossRefGoogle Scholar
  14. 14.
    Thoracic Society of Australia and New Zealand. Guidelines for the management of chronic obstructive pulmonary disease. Mod Med Aus. 1995;38:132–6.Google Scholar
  15. 15.
    Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–61.CrossRefGoogle Scholar
  16. 16.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.CrossRefGoogle Scholar
  17. 17.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.CrossRefGoogle Scholar
  18. 18.
    Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Cochrane Reviewers’ Handbook 4.2.2. Updated March 2004. Chichester: Wiley; 2004. p. 68–139.Google Scholar
  19. 19.
    Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials. 1986;7(4):267–75.CrossRefGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefGoogle Scholar
  21. 21.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefGoogle Scholar
  22. 22.
    Deeks JJ, Higgins JPT, Ad G. Chapter 9: analysing data and undertaking meta-analysis. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 501. Oxford: The Cochrane Collaboration; 2008.Google Scholar
  23. 23.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.CrossRefGoogle Scholar
  24. 24.
    Jackson IM, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study. J Int Med Res. 1984;12(3):198–206.CrossRefGoogle Scholar
  25. 25.
    British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax. 1985;40(11):832–5.CrossRefGoogle Scholar
  26. 26.
    Meister R. Langzeittherapie mit Acetylcystein Retard Tabletten bei Patienten mit chronischer Bronchitis. Eine doppelblinde-placebokontrollierte Studie (Latin). Forum des Praktischen und Allgemeinarztes. 1986;25:18–22.Google Scholar
  27. 27.
    Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J. 1988;1(4):351–5.PubMedGoogle Scholar
  28. 28.
    Hansen NC, Skriver A, Brorsen-Riis L. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994;88(7):531–5.CrossRefGoogle Scholar
  29. 29.
    Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64(6):405–15.PubMedGoogle Scholar
  30. 30.
    Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol. 1976;9(5–6):393–6.CrossRefGoogle Scholar
  31. 31.
    Borgia M, Sepe N, Ori-Belometti M, Borgia R. Confrontotra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica (Latin). Gaz Med It. 1981;140:467–72.Google Scholar
  32. 32.
    Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis. 1980;111:93–108.Google Scholar
  33. 33.
    Parr GD, Huitson A. Oral Fabrol (oral N-acetylcysteine) in chronic bronchitis. Br J Dis Chest. 1987;81(4):341–8.CrossRefGoogle Scholar
  34. 34.
    Schermer T, Chavannes N, Dekhuijzen R, et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med. 2009;103(4):542–51.CrossRefGoogle Scholar
  35. 35.
    Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet. 1965;1(7389):775–9.Google Scholar
  36. 36.
    Poole P. Methylcysteine hydrochloride in chronic bronchitis. Respir Med COPD Update. 2006;2:64–6.CrossRefGoogle Scholar
  37. 37.
    Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Methods. 2003;8(3):243–53.CrossRefGoogle Scholar
  38. 38.
    Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009;64(10):894–900.CrossRefGoogle Scholar
  39. 39.
    Manuel M, Esteban M, Concepcion G, Julio C. N-Acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol. 2011;82(5):548–55.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Respiratory and Critical Care MedicineChengdu Second People’s HospitalChengduChina
  2. 2.Graduate School of Chongqing Medical UniversityChongqingChina

Personalised recommendations